David Jensen reports on the future of CIRM as a “beautiful machine”.
CIRM funds brain cancer research in a big way: Funding a clinical trial for deadly cancer is a no brainer. Glioblastoma is a fatal tumor that needs new clinical approaches so this is exciting. One of the goals of my lab is to find new pathways to treat glioblastoma in children.
Jacob Corn of IGI has a Wish List for Science on CRISPR science, but also science more generally.
The case for possibly retracting a retraction over at RetractionWatch.
Take another look at last year’s Takaho Endo paper, which was a major step toward debunking STAP so why did the new paper in Nature debunking STAP using similar approach not cite Dr. Endo’s 2014 paper? I’m glad to see that the other new Nature paper did cite Dr. Endo’s paper.
Pete Shanks over at BioPolitical Times from CGI voices concerns about balance at upcoming NAS meeting on human gene editing.
Zhang’s lab reports on Cpf1, a useable new CRISPR partner protein in place of Cas9 and Antonio Regalado has the backstory: New CRISPR Protein Slices through Patent Problems